Regulatory Jobs

FDA's Real-Time Oncology Review Lets Reviewers Start Before the Application Is Complete

How FDA's Real-Time Oncology Review pathway changes submission sequencing for oncology drugs, and what it means for regulatory affairs workload and timing.

Connor Griggs

Connor GriggsMSRACQA

Founder & Editor-in-Chief

7 min read

Introduction

Most drug and biologic applications follow a familiar sequence: the sponsor completes the full submission, FDA logs it, a review clock starts, and the agency works through the package as a finished whole. FDA's Real-Time Oncology Review pathway, known in the field simply as RTOR, breaks that sequence apart for a specific slice of oncology applications. Instead of waiting for the complete package, FDA reviewers can begin working through key data as soon as it's ready, often before the sponsor has finished assembling the formal submission around it. For regulatory affairs teams working in oncology, that changes not just the review timeline but the internal workflow that has to support it.

This piece walks through what RTOR actually does, which applications it applies to, how it changes the regulatory affairs workload compared to a standard submission, and what teams should understand before assuming a program is eligible.

What RTOR Actually Changes

The core mechanic of RTOR is sequencing, not a lowered evidentiary bar. Under a standard review, a sponsor assembles the complete application, submits it, and the agency's substantive review begins only once the full package has been received and accepted for filing. Under RTOR, once a sponsor has topline efficacy and safety results in hand, typically from an interim or final analysis of a pivotal trial, the agency can begin reviewing that data and key supporting sections before the sponsor has finished drafting and formatting the complete submission around it.

In practice, this means FDA reviewers and the sponsor's regulatory and medical teams are working in parallel rather than in sequence. Reviewers can ask clarifying questions on the data they've already received while the sponsor continues finalizing other modules, such as the full clinical study report, labeling negotiations, or chemistry, manufacturing, and controls sections that weren't the rate-limiting piece. The goal, as FDA has described it, is to move total review time for eligible supplements and applications into a window measured in weeks rather than months, by eliminating the dead time that would otherwise sit between database lock and the start of substantive review.

A Brief History of the Pathway

FDA introduced RTOR as a pilot program within its oncology review divisions, initially scoped to supplemental applications for already-approved oncology drugs and biologics where the agency had substantial prior experience with the product and the disease setting. The thinking behind starting there was straightforward: a supplement for an existing approved product carries less unknown risk than a novel original application, which made it a reasonable place to test whether reviewing data in pieces, rather than as one complete package, could be done safely and still meet the agency's evidentiary standards. Based on that initial experience, FDA has since applied the same approach to a number of original marketing applications in oncology as well, though supplements remain the more common use case.

The pathway sits alongside, and is frequently used in combination with, FDA's other oncology-focused tools: breakthrough therapy designation, which signals that a product addresses a serious condition with preliminary evidence of substantial improvement over available therapies, and priority review, which commits the agency to a shorter standard review clock once a complete application is filed. RTOR doesn't replace either of those; it changes how and when the agency engages with the data that those designations are built around.

Which Applications Are Eligible

RTOR was built around oncology specifically, and eligibility has generally centered on applications where the agency and sponsor have already been in active dialogue, most often through existing breakthrough therapy designation, priority review expectations, or an ongoing supplemental application for an already-approved product where the agency has visibility into the trial design well before topline results arrive. It has been used most for supplemental applications, such as a new indication or dosing regimen for an oncology product already on the market, though original approvals in oncology have also used the framework in some cases.

The pathway is not a general option a sponsor can request for any oncology submission. It depends on FDA agreeing, usually during a pre-submission meeting, that the program's data package and trial design are mature enough and well enough understood by the review division to support reviewing pieces as they become available rather than as one completed package. That agreement typically needs to happen well before topline data locks, which means regulatory affairs involvement starts much earlier in the trial timeline than it would for a standard submission strategy.

What Changes for Regulatory Affairs Work

For a regulatory affairs team supporting an RTOR submission, the biggest shift is that document readiness can no longer be sequenced around a single filing date. Instead of building toward one complete package, the team is producing and quality-checking individual modules on a rolling basis, often while the clinical study report is still being finalized by medical writing and biostatistics. That requires closer, earlier coordination between regulatory affairs, clinical operations, biostatistics, and medical writing than a standard submission timeline demands, since any one of those functions falling behind becomes immediately visible to the agency rather than absorbed into an internal buffer before the formal filing date.

Labeling negotiation also tends to start earlier and run concurrently with the clinical review rather than following it, since FDA reviewers already working through efficacy and safety data can raise labeling questions well before the sponsor would otherwise expect them. Regulatory affairs professionals on these programs often describe the experience as closer to an ongoing dialogue with the review division than a single submit-and-wait cycle, which rewards teams that can turn around agency questions quickly and keep internal document version control tight across a longer, more fluid review window.

Why This Matters Beyond Oncology Teams

RTOR hasn't been formally extended as a standing pathway to other therapeutic areas, but its influence on submission thinking has spread past oncology divisions. Sponsors and regulatory affairs teams working in other serious or life-threatening disease areas have taken the underlying idea, engage the agency early, share data as it matures rather than waiting for a complete package, and applied it informally within other expedited programs like breakthrough therapy and accelerated approval, even where the formal RTOR label doesn't apply. For regulatory affairs professionals building experience with real-time or rolling review concepts in oncology, that experience is increasingly relevant background for other fast-moving submission strategies as well.

It also means that hiring managers in oncology regulatory affairs increasingly look for candidates who understand how to manage a submission that doesn't follow a single fixed filing date. That's a meaningfully different skill set from preparing one complete package against one deadline, and it rewards people comfortable with ambiguity in document timing and frequent, informal agency interaction.

Planning a Submission Strategy Around RTOR

For sponsors considering whether to pursue this pathway, the planning work starts much earlier than it would for a standard submission. Because eligibility depends on FDA's agreement that the division already understands the trial design and data package well enough to review it piecemeal, regulatory affairs teams typically need to build that shared understanding through a series of meetings well before topline results are anywhere near ready, often starting at the end-of-phase-2 meeting or an analogous checkpoint for a supplemental program. Waiting until data lock to raise the possibility with the agency is generally too late.

Internally, this means regulatory affairs has to convince clinical operations, biostatistics, and medical writing to plan their own timelines around a rolling delivery model well before anyone knows for certain whether the agency will agree to it. That's a harder internal sell than a standard submission timeline, where every function knows there's one fixed date to build toward. Teams that have done this successfully tend to treat the possibility of RTOR as a working assumption from early in the trial rather than a late-breaking opportunity, building document templates, data transfer agreements, and internal review cycles that can flex to a rolling cadence if the agency agrees to the approach, and that still work perfectly well as a standard submission if it doesn't.

What Teams Should Not Assume

A few misconceptions come up often enough to be worth naming directly. RTOR does not mean a lower bar for data quality or completeness; the agency is still reviewing the same evidentiary package it would otherwise expect, just on a different schedule. It also isn't something a sponsor can simply opt into without FDA's agreement, and that agreement typically depends on an existing relationship with the review division built well before the pivotal data matures. Finally, participating in RTOR doesn't necessarily shorten the sponsor's internal work; it often front-loads and compresses it, since modules that might otherwise be finalized over several months now need to be ready on a rolling basis as the agency works through them.

Conclusion

Real-Time Oncology Review is a sequencing change, not a shortcut, and understanding that distinction matters for anyone working in or hiring for oncology regulatory affairs. It rewards early, sustained coordination between regulatory affairs and the clinical, biostatistics, and medical writing functions that feed a submission, and it increasingly shapes how sponsors think about expedited programs even outside oncology. For regulatory professionals building a career in this space, fluency with how RTOR actually works, not just that it exists, is a real differentiator.

Regulatory & Quality. REWIRED.

New roles. Real pay. Your next move.

  • Hand-picked roles, every week.
  • The newest company pages.
  • One article worth your time.
Get the Weekly

Free. Thursday mornings. One-click unsubscribe.

Connor GriggsConnor Griggs

About the author

Connor GriggsMSRA, CQA

Founder & Editor-in-Chief

Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.

Find your next regulatory or quality role

Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.

Next in News & UpdatesWhat FDA's QMSR Means for Regulatory and Quality Careers in Medical Devices